Falcon Genomics

Falcon Genomics is a precision oncology company that leverages advanced bioinformatics to optimize cancer treatment strategies. Spun out from Rutgers University, the company utilizes its proprietary Falcon Platform to analyze complex genomic data, identifying specific molecular drivers and therapeutic vulnerabilities in tumors. Their approach focuses on detecting signatures of DNA repair deficiency and other biomarkers to guide the use of targeted therapies such as PARP inhibitors. By integrating clinical outcomes with deep genomic profiling, Falcon Genomics provides actionable insights that help oncologists personalize patient care. The company's technology aims to bridge the gap between high-throughput sequencing and clinical decision-making.